Camp - CAMP

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Camp4 Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Camp4 Therapeutics..

Camp4 Therapeutics (NASDAQ:CAMP) Azioni, Catena delle Opzioni

Camp4 Therapeutics

CalAmp

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Healthcare Workers Sound the Alarm

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

CAMP

EWTX

GNFT

Dopo il recente ribasso, queste 3 azioni sanitarie ipervendute potrebbero sorprenderti con un forte rimbalzo nel Q2.

Affari d&#39;oro nella sanità? 3 azioni ipervendute pronte al rimbalzo

<h3>Gainers</h3>
<ul>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares rose 36.0% to $0.53 during Wednesday's after-market session. The company's market cap stands at $18.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 30.43% to $0.01. The market value of their outstanding shares is at $4.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 17.01% to $13.0. The market value of their outstanding shares is at $338.1 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares rose 8.53% to $7.5. The market value of their outstanding shares is at $174.7 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 7.27% to $1.77. The market value of their outstanding shares is at $35.6 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares moved upwards by 6.79% to $5.97. The company's market cap stands at $32.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 53.4% to $0.52 during Wednesday's after-market session. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares declined by 27.48% to $0.42. The company's market cap stands at $7.7 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares fell 24.13% to $1.51. The market value of their outstanding shares is at $49.9 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 17.85% to $0.49. The market value of their outstanding shares is at $5.4 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares declined by 13.02% to $23.0. The market value of their outstanding shares is at $462.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 10.28% to $0.33. The market value of their outstanding shares is at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DERM

HCTI

HSDT

INTS

JUNS

LIMN

NUWE

SCLX

VTAK

12 Health Care Stocks Moving In Wednesday's After-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wedbush analyst Yun Zhong initiated coverage on Camp4 Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with an Outperform rating and announced a price target of $8. Camp4 Therapeutics shares closed at $2.00 on Friday. <a href="https://www.benzinga.com/quote/CAMPP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Mark Miller initiated coverage on Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Buy rating and announced a price target of $58. SanDisk shares closed at $37.28 on Friday. <a href="https://www.benzinga.com/quote/SNDK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Susan Anderson initiated coverage on Niagen Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) with a Buy rating and announced a price target of $13. Niagen Bioscience shares closed at $9.88 on Friday. <a href="https://www.benzinga.com/quote/NAGE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Arnon Shirazi initiated coverage on DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) with a Buy rating and announced a price target of $14.6. DLocal shares closed at $11.26 on Friday. <a href="https://www.benzinga.com/quote/DLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Roger Read initiated coverage on Expro Group Holdings N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPRO#NYSE">XPRO</a>) with an Overweight rating and announced a price target of $12. Expro shares closed at $7.85 on Friday. <a href="https://www.benzinga.com/quote/XPRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SNDK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27090609/image-339-1024x594.png" alt="" class="wp-image-928390" style="width:672px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27090609/image-339-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27090609/image-339-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27090609/image-339-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27090609/image-339.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

NAGE

SNDK

XPRO

This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $8.

Price Target

Initiation

Analyst Ratings

Wedbush Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $8

CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today delivered three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs and shared favorable safety and pharmacokinetics data from the ongoing Phase 1 trial of CMP-CPS-001 in healthy volunteers at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, May 13 – 17, 2025.

CAMP4 Unveils SYNGAP1 And Urea Cycle Disorder Data At ASGCT 2024, Highlighting Protein Boost And Safety Progress

Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) reported quarterly losses of $(0.62) per share. This is a 97.67 percent increase over losses of $(26.57) per share from the same period last year. The company reported $858.00 thousand in sales this quarter.

Earnings

Camp4 Therapeutics Q1 EPS $(0.62) Up From $(26.57) YoY, Sales $858.00K

<h3>Gainers</h3>
<ul>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 83.1% to $2.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 48.22% to $2.09. The company's market cap stands at $28.7 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock moved upwards by 27.6% to $2.45. The company's market cap stands at $49.3 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock moved upwards by 16.59% to $0.75. The company's market cap stands at $2.8 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares rose 15.86% to $8.4. The market value of their outstanding shares is at $49.2 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares rose 14.63% to $1.4. The company's market cap stands at $163.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 46.4% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) shares fell 19.66% to $11.2. The market value of their outstanding shares is at $265.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 16.76% to $0.4. The market value of their outstanding shares is at $9.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares declined by 12.6% to $2.36. The company's market cap stands at $140.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.26% to $0.16. The market value of their outstanding shares is at $4.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 10.98% to $0.34. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALDX

ATRA

BIAF

EKSO

GCTK

KTTA

NCNA

SXTC

TCMD

TLSA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) rose sharply in today's pre-market trading after the company announced better-than-expected first-quarter results and <a href="https://www.benzinga.com/quote/TDUP/earnings">raised its FY25 sales forecast</a>.
ThredUp posted a quarterly loss of 4 cents per share, compared to market estimates for a loss of 7 cents per share. The company's quarterly sales came in at $71.29 million versus expectations of $68.19 million.
ThredUp shares jumped 19.6% to $5.31 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) rose 76.4% to $0.2178 in pre-market trading after falling around 11% on Monday.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) surged 70.6% to $1.08 in pre-market trading after jumping around 12% on Monday.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) gained 64.5% to $2.32 in pre-market trading after dipping 38% on Monday.</li>
<li>BloomZ Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) jumped 53.4% to $0.2770 in pre-market trading after gaining 8% on Monday.</li>
<li>CAMP4 THERAPEUTICS CORPORATION (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) gained 44.3% to $2.77 in pre-market trading.</li>
<li>JBDI Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBDI#NASDAQ">JBDI</a>) surged 32.5% to $1.10 in pre-market trading after announcing a $1.0 million share repurchase program.</li>
<li>Intrepid Potash, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) gained 19.4% to $38.88 in pre-market trading following first-quarter results.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 13.1% to $7.75 in pre-market trading after the company announced it expanded its strategic partnership with Uber to bring autonomous vehicles to 15 additional cities.</li>
<li>Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 11.8% to $10.85 in pre-market trading. PONY AI and Uber announced a strategic partnership to advance autonomous mobility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cadiz Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDZI#NASDAQ">CDZI</a>) shares dipped 37.4% to $1.81 in pre-market trading.</li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 28.8% to $0.7821 in pre-market trading after jumping more than 130% on Monday.</li>
<li>BRC Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) shares fell 24.3% to $1.79 in pre-market trading after posting a wider-than-expected quarterly loss.</li>
<li>N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) fell 22.7% to $0.5250 in pre-market trading after jumping 140% on Monday.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) declined 21.6% to $0.0250 in pre-market trading. Digital Ally, on Monday, announced a reverse stock split.</li>
<li>Energys Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares tumbled 19.1% to $2.50 in pre-market trading after dipping 66% on Monday.</li>
<li>Hyperscale Data, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>) dipped 17.2% to $6.42 in pre-market trading. Hyperscale Data shares jumped 466% on Monday after the company issued FY25 sales guidance.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) fell 8.4% to $113.45 in pre-market trading. Palantir reported in-line earnings for its first quarter on Monday. Palantir reported first-quarter revenue of $883.86 million, beating analyst estimates of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates. The company also raised its full-year guidance</li>
<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) fell 7.1% to $8.31 in pre-market trading.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) fell 6.8% to $206.00 in today's pre-market trading after the company reported third-quarter results and issued fourth-quarter guidance with its midpoint below estimates.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

AIFU

BLMZ

BRCC

CDZI

DGLY

ENGS

GPUS

JBDI

MRIN

NITO

PLTR

PONY

RCUS

TDUP

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

AMRN

AMWL

ARDX

ATPC

CTSO

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented
CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025.
Details for the oral presentations are as follows:
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT
Title: A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea&nbsp;Cycle Diseases (UCDs): Interim Safety Readout Presenter: Yuri Maricich, M.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT

Biotech

General

CAMP4 Announces It Will Present New Preclinical Data From Its Urea Cycle Disorders And SYNGAP1-Related Disorders Programs At 28th American Society Of Gene And Cell Therapy Annual Meeting May13-17, 2025 In New Orleans, Lousiana

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Edgewise Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>)</h3>
<ul>
<li>On April 2, Edgewise Therapeutics priced an underwritten public offering of 9.94 million shares at $20.13 per share, expecting to raise approximately $200 million. The offering is set to close on April 3, pending customary conditions. The company's stock fell around 55% over the past month and has a 52-week low of $10.60.</li>
<li>RSI Value: 27.5</li>
<li>EWTX Price Action: Shares of Edgewise Therapeutics gained 8.8% to close at $12.50 on Wednesday.</li>
<li>Edge Stock Ratings: 15.43 Momentum score. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ewtx"><img loading="lazy" decoding="async" width="493" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png" alt="" class="wp-image-865422" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png 493w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59-300x105.png 300w" sizes="(max-width: 493px) 100vw, 493px" /></a></figure>
<h3 class="wp-block-heading">Genfit SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 7, HC Wainwright &amp; Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 27% over the past five days and <a href="https://www.benzinga.com/quote/GNFT">has a 52-week low</a> of $2.55.</li>
<li>RSI Value: 29.3</li>
<li>GNFT Price Action: Shares of Genfit dipped 21.4% to close at $2.64 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">GNFT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="921" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png" alt="" class="wp-image-865424" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-768x694.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">CAMP4 Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>)</h3>
<ul>
<li>On March 27, CalAmp reported a quarterly loss of $11.04 per share which met the analyst consensus estimate. &#8220;We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering,&#8221; said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. The company's stock fell around 49% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CAMP">low of $0.39.</a></li>
<li>RSI Value: 23.1</li>
<li>CAMP Price Action: Shares of CAMP4 Therapeutics dipped 7.4% to close at $2.14 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">CAMP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="886" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png" alt="" class="wp-image-865425" style="width:416px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png 886w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-768x716.png 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CalAmp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) reported quarterly losses of $(11.04) per share which met the analyst consensus estimate. This is a 91.15 percent increase over losses of $(124.80) per share from the same period last year.

CalAmp FY 2024 GAAP EPS $(11.04), Inline

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 81.7% to $0.87 during Tuesday's pre-market session. The company's market cap stands at $4.9 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 35.65% to $0.39. The company's market cap stands at $25.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares rose 33.5% to $2.59. The market value of their outstanding shares is at $217.0 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares moved upwards by 30.85% to $0.09. The market value of their outstanding shares is at $7.2 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares moved upwards by 18.0% to $90.1. The market value of their outstanding shares is at $2.4 billion. The company's, Q4 earnings came out today. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock moved upwards by 17.25% to $5.98. The company's market cap stands at $120.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 57.1% to $1.0 during Tuesday's pre-market session. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares fell 33.2% to $0.42. The market value of their outstanding shares is at $2.4 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 24.92% to $0.22. The company's market cap stands at $2.4 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 16.8% to $0.27. The market value of their outstanding shares is at $4.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares decreased by 15.6% to $1.84. The company's market cap stands at $6.2 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 14.8% to $0.2. The market value of their outstanding shares is at $10.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

BPTH

GLYC

IPHA

MBRX

OMGA

PTPI

RSLS

VRPX

Expected Milestones in 2025
<ul>
<li>MAD safety, pharmacokinetic and key pharmacodynamic biomarker data in healthy volunteers in the second half of 2025.</li>
<li>GLP toxicity studies of lead ASO candidate for neurodevelopmental disorders caused by SYNGAP1 mutations to be initiated this year.</li>
<li>Advance a new discovery program targeting a GBA1 regRNA to increase gene expression for the treatment of Parkinson's disease (PD) caused by mutations in GBA1, with potential for application in sporadic PD.</li>
<li>Company to focus on expanding its strategic partnerships to continue maximizing the value of its RAP platform.</li>
</ul>

CAMP4 Outlines 2025 Milestones: MAD Safety Data in H2, GLP Toxicity Studies for SYNGAP1 Disorders, New GBA1 Discovery for Parkinson's, and Strategic Partnership Expansion.

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 178.2% to $9.04 during Tuesday's pre-market session. The company's market cap stands at $10.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 137.73% to $1.26. The market value of their outstanding shares is at $235.4 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares rose 39.15% to $8.85. The company's market cap stands at $178.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) stock rose 27.53% to $1.26. The market value of their outstanding shares is at $33.3 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares moved upwards by 19.13% to $19.67. The market value of their outstanding shares is at $22.2 billion. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 17.99% to $1.18. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock decreased by 47.7% to $1.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 38.27% to $1.42. The company's market cap stands at $47.4 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares decreased by 33.49% to $3.0. The market value of their outstanding shares is at $97.7 million. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) stock declined by 31.25% to $1.98. The company's market cap stands at $156.8 million. </li>
<li>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) stock declined by 23.79% to $70.19. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 12.49% to $5.12. The company's market cap stands at $185.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKTX

BMEA

LMAT

PEPG

PRTG

RVPH

TEVA

TNXP

TNYA

VCNX

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 192.4% to $3.07 during Friday's pre-market session. The market value of their outstanding shares is at $4.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares moved upwards by 25.17% to $1.84. The market value of their outstanding shares is at $28.8 million. </li>
<li>Radiopharm Theranostics Limited - American Depositary Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares increased by 24.5% to $22.0. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 17.23% to $1.7. The market value of their outstanding shares is at $137.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock increased by 14.28% to $2.96. The market value of their outstanding shares is at $3.9 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares rose 14.12% to $0.53. The market value of their outstanding shares is at $21.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock fell 25.3% to $4.63 during Friday's pre-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock declined by 18.35% to $8.01. The market value of their outstanding shares is at $161.4 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 14.76% to $0.46. The market value of their outstanding shares is at $3.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 14.4% to $2.26. The company's market cap stands at $1.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 11.62% to $2.74. The market value of their outstanding shares is at $4.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 10.54% to $0.35. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MTEM

RADX

SLXN

SNOA

VSEE

Shares of DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) rose sharply in today's pre-market trading r after the company reported better-than-expected third-quarter financial results and issued FY25 revenue <a href="https://www.benzinga.com/news/earnings/24/12/42352653/docusign-stock-soars-on-q3-earnings-beat-revenue-beat-strong-guidance">guidance above estimates</a>.
DocuSign reported third-quarter revenue of $754.8 million, beating the consensus estimate of $745.26 million. The company reported third-quarter adjusted earnings of 90 cents per share, beating analyst estimates of 87 cents per share, according to Benzinga Pro.
DocuSign shares jumped 14.1% to $95.43 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) gained 196.2% to $3.11 in pre-market trading after dipping 41% on Thursday.</li>
<li>Zhibao Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) rose 111.7% to $5.08 in pre-market trading after the company announced they will partner with PICC &amp; Munich Re to develop new medical insurance products in China.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) gained 82.2% to $6.94 in pre-market trading after the company announced that it regained Nasdaq compliance.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) gained 48.6% to $2.11 in pre-market trading after gaining over 10% on Thursday.</li>
<li>The Lion Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEV#NYSE">LEV</a>) gained 43.3% to $0.48 in pre-market trading. Lion Electric reached a definitive agreement in respect of the sale of Innovation Center located in Mirabel, Québec for a purchase price of C$50 million.</li>
<li>Primega Group Holdings Limited  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) rose 40.1% to $1.87 in pre-market trading after dipping over 15% on Thursday.</li>
<li>Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) gained 23.2% to $66.11 in pre-market trading as the company reported better-than-expected results for its third quarter.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) climbed 21.3% to $18.75 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Satellogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) gained 12.1% to $3.52 in pre-market trading after jumping 20% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) shares tumbled 81.23 to $10.50 in pre-market trading after surging 599% on Thursday.</li>
<li>zSpace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) declined 31.7% to $15.01 in pre-market trading after jumping 340% on Thursday.</li>
<li>Foxx Development Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) shares fell 24.7% to $3.73 in pre-market trading after jumping 55% on Thursday.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 23.4% to $3.44 in pre-market trading. PainPerform shares jumped 68% on Thursday after the company announced changes in management including new CFO and CEO appointees.</li>
<li>Virpax Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) fell 21.5% to $0.3069 in pre-market trading after declining around 5% on Thursday.</li>
<li>CAMP4 THERAPEUTICS CORPORATION (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) fell 21.4% to $7.71 in pre-market trading after gaining 66% on Thursday.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) fell 17.9% to $4.94 in pre-market trading. Protare Therapeutics shares jumped 70% on Thursday after the company announced results from its ongoing Phase 2 TARA-002 trial in patients with NMIBC.</li>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) dipped 17.1% to $0.4472 in pre-market trading after jumping 60% on Thursday.</li>
<li>Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares dipped 16.7% to $1.10 in pre-market trading after jumping 94% on Thursday.</li>
<li>Smith &amp; Wesson Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) fell 15.8% to $11.48 in today's pre-market trading after the company reported second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42357598/dow-dips-more-than-200-points-ahead-of-jobs-report-investor-sentiment-declines-fear-greed-index-remains-in-greed-zone">Dow Takes A Breather After Record Close, Dips Over 200 Points Ahead Of Jobs Report: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

ASAN

DOCU

FOXX

GXAI

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

ORIS

PGHL

PRFX

RBRK

SATL

SWBI

TARA

ZBAO

ZSPC

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

CAMP4 Therapeutics Q3 EPS $(24.19), Ended Quarter With $2.5M In Cash And Cash Equivalents

In October, CAMP4 Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million <a href="https://www.benzinga.com/pressreleases/24/10/g41283554/camp4-announces-pricing-of-initial-public-offering" target="_blank" rel="noreferrer noopener">in gross proceeds</a>.
Camp4 is an RNA therapeutics company focused on developing therapies for rare diseases.
CAMP4 Therapeutics <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-cmp-cps-001-a-potential-first-in-class-therapeutic-for-urea-cycle-disorders/" rel="noreferrer noopener">dosed</a> the first participant in its Phase 1 study of CMP-CPS-001 for urea cycle disorders (UCDs) in March.
CMP-CPS-001 has secured FDA <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-orphan-drug-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Orphan</a> Drug and Rare Pediatric <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-rare-pediatric-disease-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Disease </a>Designations for urea cycle disorders.
Last month, the company announced a <a target="_blank" href="https://www.camp4tx.com/camp4-enters-strategic-research-collaboration-to-advance-novel-regulatory-rna-targeting-medicines-for-rare-genetic-conditions/" rel="noreferrer noopener">new</a> research collaboration with BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) to advance novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) sequences, key elements controlling gene expression.
Under the terms of the agreement, BioMarin has the right to select two targets identified by CAMP4's RAP Platform to advance into clinical development.
William Blair initiated coverage on CAMP4 Therapeutics, noting that Camp4&#8217;s shares trade at a significantly lower market cap than other early-stage genetic medicine companies, even though it has the innovative RAP platform. This unique platform offers a novel approach to enhancing target gene expression for rare diseases.
Piper Sandler initiated coverage on CAMP4 Therapeutics, noting that regRNAs could be the next big RNA modality with advantages over protein replacement or gene therapy.
The Piper analyst writes that any increase in ureagenesis rate test (URT) would be a signal of on-target CMP-CPS-001 ammonia lowering and provide proof-of-concept for urea cycle disorders patients.
The analyst expects CAMP4 to conduct registrational Phase 2 studies in urea cycle disorders patients and could gain FDA approval in 2029 with peak CMP-CPS-001 revenues of $1.0 billion by 2036.
Piper has initiated coverage of CAMP4 with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/CAMP/analyst-ratings" rel="noreferrer noopener">price target of $18</a>.
Price Action: CAMP stock is up 13.5% at $9.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41753070/alibaba-brings-singles-day-shopping-extravaganza-to-us-with-big-discounts" target="_blank" rel="noreferrer noopener">Alibaba Brings Singles&#8217; Day Shopping Extravaganza to US with Big Discounts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

BMRN

CAMP4 Analyst Highlights Rare Disease Platform Potential

WIIM

CAMP4 Therapeutics shares are trading higher after multiple firms initiated coverage on the stock with Overweight ratings.

William Blair analyst Myles Minter initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating.

William Blair Initiates Coverage On Camp4 Therapeutics with Outperform Rating

Press Releases

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMP4 to Participate in Upcoming Investor Conferences

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Management

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

Comments

Camp4 Therapeutics

Camp4 Therapeutics (CAMP) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO